Clinical Trials Browser

Not yet recruiting × Mesothelioma, Malignant × pembrolizumab × Clear all

NCT05425576 2024-03-15

OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition

Phase 2 Not yet recruiting

Other solid neoplasmThoracic

Mesothelioma, Malignant